Authors: Seidel, C Hjertner, O Abildgaard, N Heickendorff, L Hjorth, M Westin, J Nielsen, JL Hjorth-Hansen, H Waage, A Sundan, A Borset, M

Citation: C. Seidel et al., Serum osteoprotegerin levels are reduced in patients with multiple myelomawith lytic bone disease, BLOOD, 98(7), 2001, pp. 2269-2271

Authors: Abildgaard, N Glerup, H Rungby, J Bendix-Hansen, K Kassem, M Brixen, K Heickendorff, L Nielsen, JL Eriksen, EF

Citation: N. Abildgaard et al., Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma, EUR J HAEMA, 64(2), 2000, pp. 121-129

Authors: Rask, C Kelsen, J Olesen, G Nielsen, JL Obel, N Abildgaard, N

Citation: C. Rask et al., Danish patients with untreated multiple myeloma do not harbour human herpesvirus 8, BR J HAEM, 108(1), 2000, pp. 96-98

Authors: Seidel, C Borset, M Hjertner, O Cao, DJ Abildgaard, N Hjorth-Hansen, H Sanderson, RD Waage, A Sundan, A

Citation: C. Seidel et al., High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity, BLOOD, 96(9), 2000, pp. 3139-3146

Authors: Seidel, C Sundan, A Hjorth, M Turesson, I Dahl, IMS Abildgaard, N Waage, A Borset, M

Citation: C. Seidel et al., Serum syndecan-1: a new independent prognostic marker in multiple myeloma, BLOOD, 95(2), 2000, pp. 388-392

Authors: Turesson, I Abildgaard, N Ahlgren, T Dahl, IM Holmberg, E Hjorth, M Nielsen, JL Oden, A Seidel, C Waage, A Westin, J Wisloff, F

Citation: I. Turesson et al., Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors, BR J HAEM, 106(4), 1999, pp. 1005-1012